ValorQ4, 24Q4, 25TTMGastos comerciales, generales y administrativos———Investigación y desarrollo———Beneficio operativo———Total de ingresos no operativos———Gastos por intereses, netos de intereses capitalizados———Ingresos no operativos, una vez deducidos los gastos por intereses———Ingresos/gastos extraordinarios———Beneficio antes de impuestos-9.71 M35.4 M-17.73 MParticipación en los beneficios———Impuestos—209 K—Participación minoritaria———Otros ingresos/gastos después de impuestos———Beneficio neto antes de actividades interrumpidas-9.71 M35.19 M-17.94 MOperaciones suspendidas———Beneficio neto-9.71 M35.19 M-17.94 MAjuste por dilución———Dividendos de las acciones preferentes———Beneficio neto diluido atribuible a los accionistas-9.71 M35.19 M-17.94 MBeneficio básico por acción———Beneficio por acción diluido-0.110.38-0.23Número medio de acciones ordinarias89.53 M93.43 M357.14 MAcciones diluidas89.53 M93.82 M357.53 MEBITDA———EBIT———Costo de los ingresos———Otros costes de producción———Amortización y depreciación (flujo de caja)———
Compugen Ltd
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.